Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases.

导出 LinkOut

翻译打印收藏纠错

作者： Hiroshi,Deguchi ^[1] ; Silvia,Navarro ^[1] ; Amanda B,Payne ^[2] ; Darlene J,Elias ^[3] ; Nicole F,Dowling ^[4] ; Harland D,Austin ^[1] ; Francisco,España ^[5] ; Pilar,Medina ^[3] ; W Craig,Hooper ^[4] ; John H,Griffin ^[3]

作者单位： Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA. ^[1] Haemostasis, Thrombosis, Atherosclerosis and Vascular Biology Research Group, La Fe Medical Research Institute, Valencia, Spain. ^[2] Rollins School of Public Health, Emory University, Atlanta, GA, USA. ^[3] Division of Blood Disorders, Centers for Disease Control and Prevention, Atlanta, GA, USA. ^[4] Scripps Clinic and Scripps Green Hospital, La Jolla, CA, USA. ^[5]

关键词 epidemiology glucosylceramide myocardial infarction risk factor venous thrombosis

DOI 10.1002/rth2.12018

PMID 29202121

发布时间 2023-03-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览12

Research and practice in thrombosis and haemostasis

2017年1卷1期

33-40页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases.

Research and practice in thrombosis and haemostasis

相似文献

Research and practice in thrombosis and haemostasis

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases.

Research and practice in thrombosis and haemostasis

相似文献

Research and practice in thrombosis and haemostasis

相关期刊

检索历史清除